Search
Research
Diabetes Translational ResearchThe year 2013 saw the progress in our research from purely lab-based studies towards taking a step closer to translational research.
Research
TrialNet: Pathway to PreventionThis study is helping us to learn how type 1 diabetes develop and ways to delay and prevent it.
Research
Investigating mortality rates and the incidence and risk factors of diabetes complications and co-morbidities during early adult life in a population based childhood onset diabetes cohortUsing the WA Data Linkage System to provide information of the incidence and relative risk of T1D co-morbidities and mortality during early adulthood.
Research
The effect of oral insulin on subcutaneous insulin requirements and glycaemia in T1DMLiz Tim Davis Jones MBBS FRACP PhD MBBS DCH FRACP MD Co-director of Children’s Diabetes Centre Co-head, Diabetes and Obesity Research Co-director of
Research
Septo-optic dysplasia and gastroschisis: trends in birth prevalence and association with maternal ageThis study aims to describe the risk factors and trends in birth prevalence of septo-optic dysplasia (SOD) and gastroschisis between 1980 and 2023. This descriptive, population-based study of SOD and gastroschisis used Western Australian Register of Developmental Anomalies data from 1980 to 2023. Birth prevalence was calculated using Midwives Notification System data for all births after 20 weeks gestation.
Research
Parental experiences of using continuous glucose monitoring in their young children with early-stage type 1 diabetes: a qualitative interview studyTo explore parents' experiences of using continuous glucose monitoring in their young children with early-stage type 1 diabetes, being followed in the Australian Environmental Determinants of Islet Autoimmunity (ENDIA) study.
Research
Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetesLess than 20% of Australians with type 1 diabetes (T1D) meet recommended glucose targets. Technology use is associated with better glycaemia, with the most advanced being automated insulin delivery (AID) systems, which are now recommended as gold-standard T1D care. Our Australian AID trial shows a wide spectrum of adults with T1D can achieve recommended targets. Other studies, including lived experience data, are supportive. Insulin pumps are not subsidised for most Australian adults with T1D. We advocate change.
Research
Clinical Outcomes with MiniMedTM 780G Advanced Hybrid Closed-Loop Therapy in 2- to 6-Year-Old Children with Type 1 DiabetesAdvanced hybrid closed-loop (AHCL) therapy with the Medtronic MiniMed™ 780G system improves glycemia; however, the clinical outcomes in younger children remain less established. This pilot study aimed to explore the continuous glucose monitoring (CGM) metrics in very young children on AHCL. Children between 2 and 7 years of age and on insulin pump therapy were recruited.
Research
Hybrid Closed-Loop Versus Manual Insulin Delivery in Adults With Type 1 Diabetes: A Post Hoc Analysis Using the Glycemia Risk IndexGlycemia risk index (GRI) is a novel composite metric assessing overall glycemic risk, accounting for both hypoglycemia and hyperglycemia and weighted toward extremes. Data assessing GRI as an outcome measure in closed-loop studies and its relation with conventional key continuous glucose monitoring (CGM) metrics are limited.